Biophysics and Nuclear Medicine

核医学和医学物理核心将在核医学、医学成像、 剂量学、免疫动力学、放射化学、干细胞和免疫细胞的先进分子成像。 这一核心是前几年赠款的延续，并一直在支助工作中持续运作 自1988年以来一直担任免疫学PO1。资源继续改善，现在包括高级动物和 人体成像设施用于成像和实验研究，几笔大笔赠款提供了支持 对于成像技术的发展，这加强了对免疫学PO1核心的支持。 其中包括：综合癌症中心赠款(Varmus，PI)；活体细胞和分子 成像中心P50，(Larson/Blasberg，Co-Pi‘s)生物医学工程伙伴关系，(Ling，PI)和 乳房PO1的成像核心(Larson，Pi)和基因治疗计划项目(Sadelain，Pi)。 项目1-4广泛利用核心经验和资源来规划和实施其 明确的目标。特别是，该核心将协助项目1进行铋的成像和阿尔法剂量测定。 213和Ac-225衰变，包括量化分支影响的复杂问题 涉及多个新陈代谢不同的子代的级联。对于项目2，核心将提供 基于In-SPECT的A-33全免疫球蛋白和抗体形式的定量成像和剂量测定 111，镓-66、68和Y-86的正电子发射光谱。对于项目3，转基因免疫细胞，特别是树突状细胞 细胞将在组织水平上进行成像，可能是非侵入性的，使用绿色荧光蛋白、生物发光或 核方法。对于项目4，转基因的骨髓干细胞将使用 生物发光、绿色荧光和核成像方法的组合，取决于 需要解决的问题和量化的必要性。

The Nuclear Medicine and Medical Physics CORE will provide support in nuclear medicine, medical imaging, dosimetry, immunokinetics, radiochemistry, advanced molecular imaging of stem cells, and immune cells. This CORE is a continuation from prior years of the grant, and has been in continuous operation in support of the Immunology PO1 since 1988. Resources continue to improve and now include advanced animal and human imaging facilities for imaging and experimental studies, Several large grants have provided support for imaging technology development, which have strengthened the support for this immunology PO1 core. These include: the Comprehensive Cancer Center Grant (Varmus, PI); In Vivo Celllular and Molecular Imaging Center P50,(Larson/Blasberg, Co-Pi's) the Biomedical Enginneering Partnership,(Ling, PI) and the Imaging CORE of the Breast PO1, (Larson, PI), and the Gene Therapy Program Project (Sadelain, PI). Projects 1-4 make extensive use of CORE experience and resources in planning and implementing their specific aims. In particular, the CORE will assist project 1 with the imaging and alpha dosimetry of Bismuth- 213 and Actinium-225 decay, including the complex problem of quantifying the effect of a branching cascade involving multiple daughters with differing metabolism. For project 2, the CORE will provide quantitative imaging and dosimetry of whole IgG and antibody forms of A-33, based on SPECT of Indium- 111, and PET of Gallium-66, 68 and Yttrium-86. For Project 3, transfected immune cells, especially dendritic cells will be imaged, at the histologic level and possibly non-invasively, with GFP, bioluminescence, or nuclear methodologies. For project 4, transfected bone marrow stem cells will be imaged, using a combination of bioluminescent, GFP and nuclear imaging methodologies, depending on the level of resolution required and the need for quantification.